XNYS
PHR
Market cap658mUSD
Oct 08, Last price
10.66USD
1D
1.52%
1Q
-0.56%
IPO
-55.58%
Name
Phreesia Inc
Chart & performance
P/E
285.74
P/S
1.37
EPS
0.04
Div yield, %
—
Shrs. gr., 5y
9.25%
Rev. gr., 5y
26.45%
Revenues
481m
+14.48%
Net income
2m
P
CFO
79m
+143.40%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Phreesia, Inc. offers a comprehensive, cloud-based software-as-a-service (SaaS) and payment platform specifically designed for the healthcare industry in the United States and Canada. Its flagship Phreesia Platform streamlines the patient intake process and facilitates integrated patient payment processing. The platform is accessible via multiple modalities, including Phreesia Mobile (a patient-facing mobile application), Phreesia Dashboard (a web-based portal for healthcare clients), self-service tablets known as PhreesiaPads, and on-site Arrivals Kiosks. The Phreesia Platform integrates a suite of specialized modules: An automated patient self-registration system. A revenue cycle management solution providing insurance verification, point-of-sale payment applications, and cost estimation tools. Access solutions for online appointment scheduling, reminders, and referral tracking. A life sciences solution delivering targeted, clinically relevant marketing content to patients. Additionally, a clinical support solution gathers clinical intake and patient-reported outcome (PRO) data across approximately 25 specialties, and enables healthcare clients to communicate with patients via surveys, announcements, text and email messaging, and health campaigns. Dedicated COVID-19 support modules assist with vaccine delivery management, identifying vaccine-hesitant individuals, screening for risk factors, facilitating contactless check-in, and managing telehealth visit intake. Phreesia serves a diverse clientele, including individual patients; single and multi-specialty practices, along with health systems; and pharmaceutical, medical device, and biotechnology firms. Established in 2005, the company maintains its headquarters in Raleigh, North Carolina.
Key people
Thomas Altier
Chief Financial Officer
David Linetsky
Senior Vice President - Life Sciences · since 2019
Michael J. Davidoff
Senior Vice President - Marketing and Business Development · since 2019
Amy Beth VanDuyn
Senior Vice President - Human Resources · since 2019
Chaim Edwards Indig
Chief Executive Officer, Director
Edward Cahill
Independent Director · since 2007
Independent Director · since 2019
Cheryl Pegus
Independent Director · since 2019
Scott Perricelli
Independent Director · since 2014
Mark Smith
Independent Director · since 2018
Michael Weintraub
Independent Chairman of the Board
Legal address
C/O UNITED AGENT GROUP INC.
1521 CONCORD PIKE
SUITE 201
WILMINGTON, DE 19803
US
1521 CONCORD PIKE
SUITE 201
WILMINGTON, DE 19803
US
Headquarters
1521 CONCORD PIKE
SUITE 201
WILMINGTON, DE 19803
US
SUITE 201
WILMINGTON, DE 19803
US
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2026‑01 | 2025‑01 | 2024‑01 | 2023‑01 | 2022‑01 | 2021‑01 | 2020‑01 | 2019‑01 | 2018‑01 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||